MarketCapExport financials
ICON Public Limited Company (ICLR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ICON Public Limited Company Cash Flow 2025-2007 | ICLR
Brief overview of ICON Public Limited Company's cash movements
This overview follows the five latest available annual observations in the 2021–2025 interval.
Cash from operations rose +25%, from $829.1 million to $1 billion; average growth of 5.7% was consistent.
Operating cash flow stayed positive in five out of five periods. The business consistently converted operations into cash.
Across five periods, operating cash flow equaled about 2.24x of cumulative net income. Earnings were strongly backed by cash.
Cash from operations as a share of revenue remained near its former level: 12.6% after 15.1%.
Cash flow takeaway
Cash flow data show that ICON Public Limited Company has good financial flexibility and converts operating results into cash effectively.
Annual Cash Flow ICON Public Limited Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
1.04 B | 1.29 B | 1.16 B | 563 M | 829 M | 568 M | 413 M | 269 M | 383 M | 259 M | 279 M | 170 M | 221 M | 113 M | 20.2 M | 87.4 M | 255 M | 81.3 M | - |
Depreciation & Amortization |
383 M | 488 M | 586 M | 570 M | 315 M | 66.1 M | 61.6 M | 65.9 M | 61.3 M | 59.6 M | 57.7 M | 52.5 M | 46.5 M | 42.8 M | 38.7 M | 33.9 M | 32.7 M | 27.7 M | - |
Accounts Payables |
192 M | 173 M | 132 M | 81.2 M | 90.8 M | 51.1 M | 24 M | 13.3 M | 18.6 M | 8.7 M | 7.02 M | 2.79 M | 4.59 M | 8.15 M | 5.34 M | 12.3 M | 12.1 M | - | - |
Accounts Receivables |
1.47 B | 1.39 B | 1.76 B | 1.73 B | 1.34 B | 715 M | 528 M | 415 M | 380 M | 416 M | 409 M | 371 M | 343 M | 285 M | 201 M | 165 M | 192 M | - | - |
Total Inventories |
- | - | - | - | 5.8 M | 4.8 M | 3.2 M | 2.3 M | 2.2 M | 2.4 M | 1.8 M | 1.7 M | 2.2 M | 3 M | 2.8 M | 3.8 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow ICON Public Limited Company
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | 2007-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 281 M | 167 M | 234 M | 388 M | 146 M | 268 M | 338 M | 403 M | 219 M | 327 M | 440 M | 342 M | 204 M | 176 M | -59.4 M | 214 M | 182 M | 227 M | 290 M | 299 M | 128 M | 112 M | 195 M | 112 M | 118 M | 143 M | 134 M | 161 M | 22.7 M | 94.6 M | 60.9 M | 128 M | 39.2 M | 40.5 M | 106 M | 109 M | 9.09 M | 159 M | - | - | - | - | - | - | 28.1 M | 61.1 M | 75.2 M | 111 M | -54.9 M | 38.7 M | 97.4 M | 43.6 M | 10.8 M | 69.4 M | 12 M | 29.3 M | 11.5 M | 60.6 M | 37.8 M | -5.97 M | -6.38 M | -5.28 M | 87.4 M | 255 M | 81.3 M | - |
Depreciation & Amortization |
46.2 M | 50.1 M | 50.3 M | 50.5 M | 58.7 M | 59.1 M | 58.9 M | 59.3 M | 58 M | 116 M | 116 M | 116 M | 146 M | 145 M | 145 M | 35.8 M | 142 M | 144 M | 141 M | 76.9 M | 141 M | 17.3 M | 4.68 M | 4.81 M | 16.8 M | 15.9 M | 4.91 M | 4.38 M | 15.2 M | 15.2 M | 3.92 M | -223 K | 17.1 M | 17 M | 5.05 M | 4.49 M | 16.3 M | 14.4 M | 4.43 M | 4.7 M | 14.5 M | 14.5 M | 4.96 M | 4.97 M | 14.4 M | 14.2 M | 4.02 M | 2.93 M | 13.7 M | 12.9 M | 1.87 M | 2.1 M | 11.6 M | 11.5 M | 1.74 M | 1.54 M | 10.6 M | 10.8 M | 2 M | 2.11 M | 9.67 M | 9.33 M | 636 K | 33.9 M | 32.7 M | 27.7 M | - |
Accounts Payables |
86 M | 118 M | 99.8 M | 192 M | 113 M | 94.5 M | 118 M | 173 M | 106 M | 83 M | 114 M | 132 M | 87.3 M | 46.9 M | 85.1 M | 81.2 M | 60.9 M | 77.6 M | 63.5 M | 90.8 M | 62.6 M | 37.8 M | 48.1 M | 51.1 M | 28.7 M | 32.7 M | 23.3 M | 24 M | 20.8 M | 20.2 M | 19.3 M | 13.3 M | 15.3 M | 15.1 M | 11.8 M | 18.6 M | 13 M | 7.86 M | 13.6 M | 8.7 M | 5.05 M | 6.12 M | 5.65 M | 7.02 M | 4.53 M | 6.3 M | 3.86 M | 2.79 M | 5.91 M | 10.9 M | 6.66 M | 4.59 M | 8.85 M | 11.8 M | 6.79 M | 8.15 M | 9.33 M | 8.07 M | 5.49 M | 5.34 M | 6.52 M | 4.29 M | 8.61 M | 12.3 M | 12.1 M | - | - |
Accounts Receivables |
1.51 B | 1.46 B | 1.47 B | 1.47 B | 1.39 B | 1.37 B | 1.39 B | 1.39 B | 1.4 B | 1.57 B | 1.7 B | 1.76 B | 1.85 B | 1.76 B | 1.8 B | 1.73 B | 1.44 B | 1.36 B | 1.37 B | 1.34 B | 1.34 B | 677 M | 660 M | 715 M | 511 M | 473 M | 526 M | 528 M | 408 M | 432 M | 415 M | 415 M | 373 M | 405 M | 394 M | 380 M | 345 M | 360 M | 341 M | 416 M | 404 M | 367 M | 362 M | 409 M | 387 M | 358 M | 362 M | 371 M | 373 M | 383 M | 338 M | 343 M | 360 M | 306 M | 261 M | 285 M | 231 M | 228 M | 195 M | 201 M | 197 M | 171 M | 188 M | 165 M | 192 M | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.8 M | - | - | - | 4.8 M | - | - | - | 3.2 M | - | - | - | 2.3 M | - | - | - | 2.2 M | - | - | - | 2.4 M | - | - | - | 1.8 M | - | - | - | 1.7 M | - | - | - | 2.2 M | - | - | - | 3 M | - | - | - | 2.8 M | - | - | - | 3.8 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company ICON Public Limited Company, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |